Nov 21, 2025 12:07PM

Sep 19, 2025 05:00PM

Sep 19, 2025 05:00PM

Sep 5, 2025 07:51PM

Sep 5, 2025 07:50PM

Aug 11, 2025 07:28PM

Aug 11, 2025 07:28PM Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement

Jul 30, 2025 08:21PM

Jul 8, 2025 05:10PM

Jun 4, 2025 06:55AM

May 12, 2025 02:07PM

Apr 10, 2025 07:00AM

Mar 19, 2025 09:14AM

Mar 3, 2025 08:00AM DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis

Feb 3, 2025 05:00PM

Jul 2, 2024 01:58PM

Jun 12, 2024 09:05AM

Mar 27, 2024 09:08AM

Feb 26, 2024 04:05PM

Jan 31, 2024 05:06PM

Jan 24, 2024 05:55PM Revive Therapeutics Ltd. Announces Offering of Up to $3 Million

Dec 20, 2023 12:54PM

Oct 11, 2023 08:50AM

May 2, 2023 06:00AM

Apr 18, 2023 06:44PM

Apr 3, 2023 07:00AM

Mar 28, 2023 07:00AM

Mar 20, 2023 08:28AM Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Mar 8, 2023 07:45AM

Feb 6, 2023 08:00AM

Feb 6, 2023 08:00AM

Feb 3, 2023 06:00AM

Jan 19, 2023 04:50PM

Jan 12, 2023 01:14PM

Jan 12, 2023 06:00AM Revive Therapeutics Ltd. Closes $4.3 Million Offering

Jan 9, 2023 03:34PM

Jan 5, 2023 09:19AM

Dec 22, 2022 02:00PM

Dec 15, 2022 07:29AM

Nov 30, 2022 05:43PM

Nov 24, 2022 09:18AM

Nov 22, 2022 09:20AM Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Oct 14, 2022 01:34PM

Oct 6, 2022 10:18AM

Sep 28, 2022 07:00AM

Sep 16, 2022 06:00AM

Sep 14, 2022 06:00AM

Aug 16, 2022 06:00AM

Jul 25, 2022 10:57AM Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Jun 24, 2022 11:41AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All